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The absolute number of CD4 lymphocytes in blood is prognostic for disease progression, yet the cell surface
density of CD4 receptors or chemokine receptors on a single cell has not previously been found to be predictive
of human immunodeficiency virus (HIV) infectivity outcome. It has recently been shown that human leukocyte
elastase (HLE) and its ligand 1 proteinase inhibitor (1PI; 1 antitrypsin) act as HIV fusion cofactors. The
present study shows that decreased HIV infectivity is significantly correlated with decreased cell surface
density of HLE but not with decreased CD4 nor chemokine receptors. In vitro HIV infectivity outcome in this
study was predicted by the surface density of HLE on mononuclear phagocytes but not on lymphocytes. The set
point HLE surface density was in part determined by 1PI. Decreased circulating 1PI was correlated with
increased cell surface HLE and with increased HIV infectivity. The correlation of HIV infectivity outcome with
surface HLE and circulating 1PI supports the utility of these HIV cofactors in diagnostic analysis and
therapeutic intervention.
We previously demonstrated that cell surface human leuko-
cyte elastase (HLE) specifically and reversibly binds the HIV
fusion domain (Bristow et al. [3]). We have recently found that
human immunodeficiency virus (HIV) preferentially binds to
copatches of HLE, CD4, and chemokine receptors (C. L. Bris-
tow et al., unpublished data). HIV receptors were found to
copatch in response to 1proteinase inhibitor (1PI) poten-
tially explaining the requirement for 1PI during HIV entry.
These studies led to the hypothesis that 1PI might impact
HIV disease progression. Indeed, in a study of HIV-seroposi-
tive patients, we recently found that decreased circulating 1PI
is significantly correlated with decreased viral load (3a). The
prognostic value of measuring 1PI was found to be compara-
ble to measuring CD4 and considerably better than measuring
HIV RNA. During the asymptomatic category of HIV disease,
100% patients were found to manifest deficient levels of active
1PI. In contrast, circulating levels of the proteinase inhibiting
2 macroglobulin (2M) in this patient population were not
significantly different from those of normal controls. Individu-
als with the inherited form of 1PI deficiency, especially males,
are notably susceptible to respiratory infections, and 80% who
survive to adulthood succumb to respiratory failure between
the fourth and sixth decades of life (1). This suggests that the
1PI deficiency acquired during HIV infection could provide a
mechanistic explanation for the onset of attendant infections
and inflammation which subsequently initiate an increase in
1PI. Recent evidence has suggested that increased HIV is
produced by blood cells from individuals having the inherited
form of 1PI deficiency (6). To further investigate the possi-
bility that variation in circulating 1PI concentrations might
directly impact HIV infectivity outcome of peripheral blood
mononuclear cells (PBMC), in vitro infectivity of PBMC from
HIV-nonexposed individuals having the inherited form of 1PI
deficiency was compared in the presence and in the absence of
exogenous 1PI in autologous serum.
MATERIALS AND METHODS
Subjects. Blood was collected from eight different HIV-seronegative healthy
volunteers after we obtained informed consent. Subjects were selected to rep-
resent a range of 1PI concentrations in serum. All subjects were normally
healthy; however, the female counterpart from a pair of siblings homozygous for
the 1PI-deficient genotype PIZZ (2) was included for comparison despite her
history of systemic lupus erythematosis.
Quantitation of 2M and 1PI. Sera were measured at the time of collection
for 2M, as well as for active- and inactive-1PI concentrations. Methods for
quantitating active and total 1PI have been described elsewhere (2). Active 2M
and 1PI concentrations were determined by elastase inhibitory capacity. Total
1PI was determined by enzyme-linked immunosorbent assay. Inactive 1PI was
expressed as the difference between total 1PI and active 1PI.
Active-site standardization of exogenous 1PI. Active-site standardization was
performed as previously described (2). One mole of active-site titrated porcine
pancreatic elastase, type 1 (EC 3.4.21.36; Sigma) was found to saturate 3.06
moles 1PI (Sigma), suggesting that this preparation was 32.7% active.
In vitro HIV infectivity of mononuclear cells. PBMC were isolated by Ficoll-
Hypaque gradient centrifugation from whole blood collected in tubes containing
ACD (Becton Dickinson, San Jose, Calif.). Three primary non-syncytium-induc-
ing HIV type 1 (HIV-1) clinical isolates were generously provided by the Ret-
rovirology Core Laboratory, UNC–Chapel Hill. In vitro infectivity outcome was
determined by quantitating p24 accumulation or reverse transcriptase (RT)
activity as previously described (3, 5). Isolated PBMC were resuspended and
maintained in the wells of a 96-well tissue culture plate at 2  106 cells/ml in
RPMI 1640 containing 20% autologous serum and 10% interleukin-2 (Cellular
Products, Buffalo, N.Y.). PBMC in 100 l in autologous medium were stimulated
by the addition of 5 g of phytohemagglutinin (PHA; Sigma) per ml for 3 days
at 37°C in humidified 5% CO2. Cells were washed and resuspended in fresh
autologous medium containing various concentrations of exogenous active-site
standardized 1PI (Sigma).
For the determination of RT activity, PHA-stimulated PBMC were incubated
with a 8  108 50% tissue culture infective dose (TCID50) of HIV-1 for 2 h at
37°C and 5% CO2. Cells were subsequently washed three times, resuspended,
and cultured in fresh autologous medium containing matched exogenous 1PI.
Aliquots of 50 l of culture supernatants were collected and replaced with fresh
autologous medium containing matched exogenous 1PI every other day on days
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2 through 8. Culture supernatants were stored at 80°C for analysis of the RT
activity.
For the determination of the p24 accumulation, PHA-stimulated PBMC were
incubated with 10 or 40 TCID50 of HIV-1 for 2 h at 37°C and 5% CO2. Cells were
subsequently washed three times and resuspended in fresh autologous medium
and cultured at 3  106 cells/1.5 ml/well. Aliquots of 225 l were removed each
day for p24 determination (without the replacement of fresh media) on days 2
through 7. Cell counts and viability were determined at the final time point. In
the uninfected cell controls, (1.68  0.36)  106 PBMC were 96%  7% viable.
In the infected cells, (2.39  0.37)  106 PBMC were 88%  3% viable.
Immunofluorescent staining and flow cytometric analysis. Three-parameter
flow cytometric analysis using direct immunofluorescent staining of whole blood
was performed on a FACScan flow cytometer (Becton Dickinson) using fluores-
cein isothiocyanate (FITC), phycoerythrin (PE), and peridinin chlorophyl pro-
tein (PerCP) by using methods recommended by the manufacturer. To detect
chemokine receptors, blood was stained simultaneously in a single step with
three monoclonal antibodies which included (i) anti-CD14-FITC, anti-CCR5-
PE, and anti-CD4-PerCP (PharMingen, San Diego, Calif.); (ii) anti-CD14-FITC,
anti-CXCR4-PE, and anti-CD4-PerCP (PharMingen); or (iii) anti-CD14-FITC,
immunoglobulin G2a (IgG2a)-PE, and anti-CD4-PerCP (PharMingen). To de-
tect cell surface HLE, blood was stained stepwise with three antibodies, including
polyclonal sheep anti-HLE-FITC (Biodesign, Inc., Kennebunkport, Maine),
monoclonal anti-CXCR4-PE (PharMingen), and monoclonal anti-CD4-PerCP
(Becton Dickinson). The isotype-matched controls were IgG2a-PE, IgG1-PerCP,
or nonspecific IgG-FITC. Blood was washed in 2 ml of phosphate-buffered saline
between each staining step.
For each analysis, 30,000 events were acquired. List mode multiparameter data
files were analyzed using CellQuest Software (Becton Dickinson). Because the
fraction of CD4 lymphocytes and CD4 mononuclear phagocytes varied con-
siderably between individuals, the fluorescence intensity was normalized to the
CD4 cells in the gate containing either lymphocytes or mononuclear phago-
cytes. The relative geometric mean fluorescence intensities (RFI) were deter-
mined as geometric mean fluorescence intensity (MFI) relative to CD4  geo-
metric MFI of coreceptor/geometric MFI of CD4.
RESULTS AND DISCUSSION
Influence of 1PI on HIV-1 produced by PBMC infected in
vitro. To determine whether 1PI might influence HIV infec-
tivity, healthy volunteers were selected to represent a range of
circulating 1PI levels (Table 1). PBMC from these individuals
were infected in vitro using three concentrations of a non-
syncytium-inducing clinical isolate of HIV-1. PBMC were
maintained at all times in autologous serum containing various
concentrations of exogenous 1PI. We have observed that cir-
culating 1PI significantly impacts the adherence of PBMC to
tissue culture tubes (r2  0.81, P  0.0001; data not shown). To
avoid exclusion of adherent cell populations, isolated PBMC
were stimulated, infected, and cultured without removal from
their original tissue culture wells. Cultures were performed in
duplicate, and supernatants were collected and replaced with
fresh medium every other day for the determination of RT
activity.
In the absence of exogenous 1PI, RT activity was negligible
regardless of the cell source (Fig. 1) or viral inoculum (data not
shown). However, in the presence of exogenous 1PI, RT
TABLE 1. Coreceptor levels and circulating 1PI and 2M in HIV-seronegative volunteers
Subject Sexa 2M concn(M)b
1PI concn
(M)b
Lymphocyte (MFI)c Mononuclear phagocytes (MFI)c
CD4 CCR5 CXCR4 HLE CD4 CCR5 CXCR4 HLE
1 M 5.65 1.9 105 31 24 176 16 23 39 257
2 F 5.57 3.0 98 25 101 190 25 32 112 341
3 F 5.12 11.0 109 11 32 165 19 17 42 248
4 M 3.53 34.0 114 17 71 245 14 21 50 167
5 M 3.34 42.4 97 21 109 178 32 43 63 325
6 F 3.26 61.2 121 13 50 178 19 15 19 177
7 F 3.50 13.7 ND ND ND ND ND ND ND ND
8 M 5.57 39.5 ND ND ND ND ND ND ND ND
a M, male; F, female.
b Active concentration determined by elastase inhibition.
c Geometric mean fluorescence was detected by flow cytometry. Lymphocytes identified by forward and side scatter were gated to represent the CD4 population.
Mononuclear phagocytes identified by forward and side scatter were gated to represent the CD4 CD14 population. CCR5, CXCR4, and HLE are represented as
the geometric mean fluorescence intensity (MFI) within gated cells. ND, not determined.
FIG. 1. In vitro HIV infectivity of PBMC in the presence of exog-
enous 1PI. (a) Infection outcome using a non-syncytium-inducing
clinical isolate of HIV-1 was determined in duplicate by measuring the
RT activity produced by PBMC from subjects 1 (■ ), 2 (Œ), 3 (), 4
(}), 5 ( ), and 6 (F), represented in Table 1 in the absence or
presence of 3 or 30 M exogenous 1PI in autologous serum. Mean
values are depicted. (b) On day 8, the RT activity in the culture
supernatants increased as the exogenous 1PI concentration increased.

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activity was detected in PBMC from three subjects. These
three subjects were found to constitutively manifest deficient
circulating 1PI. New virus increased as circulating 1PI de-
creased (r2  0.95, P  0.001). In contrast, new virus increased
in a manner dependent upon increasing active 1PI tissue
culture concentration. These results suggest the hypothesis
that cells conditioned in vivo by increased concentrations of
1PI are less sensitive and less responsive to 1PI in tissue
culture, perhaps due to downregulation of an HIV coreceptor.
Two of the subjects studied are known to be homozygous for
the PIZZ genotype (2). The phenotype of the third subject is
not known; however, the 1PI levels (11 M) in this subject are
inconsistent with PIZZ. This suggests that 1PI levels, but not
the genotype producing 1PI deficiency, determine HIV out-
come.
To further investigate the influence of circulating 1PI on
HIV infectivity of PBMC, p24 production was determined in
cells infected in vitro in autologous serum. Active levels of
circulating 1PI were again found to be related to p24 produc-
tion; the lower the concentration of 1PI in serum, the greater
the p24 produced (Fig. 2). That p24 produced by cells infected
with 40 TCID50 was proportionally greater than by cells in-
fected with 10 TCID50 suggests that infectious dose was a
primary determinant in p24 synthesis. Because p24 accumu-
lates in tissue culture supernatants under these conditions,
comparing HIV produced by PBMC from these individuals
was facilitated by determining the rate of accumulation. It was
found that the levels of 1PI were significantly correlated with
the rate of p24 accumulation prior to day 4 when cells were
exposed to either infectious dose. In contrast, the rate of p24
accumulation after day 4 was equivalent regardless of the
PBMC source or individual 1PI concentration in serum.
These results are consistent with previous evidence using ho-
mogeneous cell populations, suggesting that once an infection
is initiated in vitro, subsequent infectious cycles are kinetically
indistinguishable (4). That the rate of p24 accumulation prior
to day 4 maintained the rank order of all five individuals at
either infectious dose suggests that p24 synthesis was not lim-
ited by the capacity of the infected cells for new protein syn-
thesis but was limited by the number of initially infected cells
in a manner determined by the infectious dose. In vitro HIV
infectivity of PBMC is notoriously variable; however, the con-
sistency of results in three independent experiments with eight
individuals representing a range of 1PI concentrations in se-
rum supports the hypothesis that 1PI is a physiologically rel-
evant cofactor for HIV. One of the individuals in this study has
been found routinely to have normal active 1PI levels (40
M) but at the time of the current study exhibited an unusually
low level (13.7 M). This further supports the conclusion that
it is the 1PI level, and not the 1PI phenotype, which influ-
ences HIV outcome.
It has previously been reported that 1PI inhibits HIV in-
fectivity (6). Evidence presented here suggests that 1PI facil-
itates HIV infectivity. We have recently found that 1PI pro-
duces a short-lived window for HIV entry (unpublished
results). HIV coreceptors are initially disperse, are stimulated
to copatch within 15 min of exposure of cells to 1PI, and then
pinch off from the plasma membrane following a period of 30
to 60 min, forming small platelet-like transitory cytoplasmic
bodies (SPTBalls). The corresponding disappearance of HIV
infectivity and the appearance of SPTBalls suggests the possi-
bility that SPTBalls may serve to uncouple cellular responsive-
ness including HIV entry.
Influence of circulating 1PI on HIV coreceptor density.
The relationship between infectivity and coreceptor densities
was compared using blood collected from the same six volun-
teers as those for which RT activity was measured. We have
observed that cell surface HLE on promonocytic cells appears
to be increased when the cells are interacted with antibodies
specific for CD4 first and specific for HLE secondarily and
then decreased when the order of antibody addition is reversed
(C. L. Bristow, unpublished data). When blood was first re-
acted with anti-HLE and secondarily with anti-CD4 or anti-
bodies specific for CXCR4 or CCR5, HLE density was negli-
gible on CD4 lymphocytes or CD4 CD14 mononuclear
phagocytes (Fig. 3). When blood was reacted with antibodies in
the reverse order, considerable levels of HLE were detected on
both CD4 lymphocytes and CD4CD14 mononuclear
phagocytes. In contrast, the order of coreceptor ligation had no
influence on the fluorescence intensities of CD4, CD14, CCR5,
or CXCR4 (data not shown). These results suggest a dynamic
FIG. 2. Correlation between the rate of HIV p24 production and
the circulating 1PI concentration. (a) PBMC were infected with 10 or
40 TCID50, and the infectivity outcome was determined by measuring
p24 accumulation. PBMC from subjects 1 (■ ), 3 (Œ), 4 (), 7 (}), and
8 ( ) represented in Table 1 were infected with a non-syncytium-
inducing clinical isolate of HIV-1 and cultured in autologous serum.
(b) The rate of p24 accumulation was calculated as the difference in
p24 between consecutive measurements. The computer-fit linear re-
gression curve for 10 TCID50 is log [y]  1.29  0.03 log [x] (r
2  0.93,
P  0.008) and for is 40 TCID50 is log [y]  1.81  0.04 log [x] (r
2 
0.95, P  0.005), where y represents 	p24 and x represents active
serum 1PI.

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functional association between membrane-associated HLE
and the HIV coreceptors CD4, CXCR4, and CCR5. As would
be expected, receptor densities were found to vary in the sub-
jects examined here without any obvious pattern (Table 1). For
example, a low receptor density for one receptor was not re-
lated to a concordantly low or high receptor density for any
other receptor. Nor was RT activity found to be related to the
receptor densities of any HIV coreceptors examined (Fig. 3).
Since the fractions of CD4 lymphocytes and CD4 mononu-
clear phagocytes varied considerably between individuals, the
fluorescence intensity of coreceptors was normalized to CD4
cells and was expressed as RFI. Increased HLE RFI, but nei-
ther the CXCR4 nor the CCR5 RFI value on CD4 CD14
mononuclear phagocytes was found to be directly correlated
with increased RT activity (r2  0.81, P  0.01; Fig. 4). These
results suggest increased cell surface HLE molecules associ-
ated with each CD4 molecule resulted in increased RT activity.
In contrast, RT activity was not related to the RFI for any
coreceptors on CD4 lymphocytes. Nor was RT activity re-
lated to RFI when coreceptors were expressed relative to
CXCR4 or CCR5 (data not shown). Consistent with these
results, when coreceptors were expressed as the fluorescence
intensity relative to HLE, increased RT activity was found to
be related to CD4 on CD4 CD14 mononuclear phagocytes
but not to either CXCR4 or CCR5 (data not shown). In this
case, increased numbers of CD4 molecules associated with
each HLE molecule resulted in decreased RT activity. These
results suggest that, although all coreceptors may participate
during HIV entry, the ratio of cell surface of HLE and CD4,
but neither CXCR4 nor CCR5, is determinant during HIV
infectivity outcome.
As was found for RT activity, decreased cell surface HLE
relative to CD4 on CD4CD14 mononuclear phagocytes was
correlated with increased circulating 1PI (r
2  0.95, P 
0.0008). Neither circulating 1PI, nor 2M was related to
CXCR4 or CCR5 relative to CD4 on CD4 CD14 mononu-
clear phagocytes or any coreceptors on CD4 lymphocytes.
FIG. 3. Relationship between RT activity and HIV coreceptor ex-
pression. PBMC from subjects 1 to 6 represented in Table 1 were
analyzed for coreceptor levels using three-color flow cytometry. (a)
Whole blood first interacted with anti-CD4 and second with anti-HLE
(tightly dotted line) exhibited considerable HLE on the cell surface of
CD4 CD14 mononuclear phagocytes (left panel) and CD4 lym-
phocytes (right panel) compared with isotype controls (loosely dotted
line). In contrast, blood first interacted with anti-HLE and secondly
with anti-CD4 (solid line) exhibited diminished HLE. Two represen-
tative subjects are depicted. (b) The RT activity produced by subjects
1 (■ ), 2 (Œ), 3 (), 4 (}), 5 ( ), and 6 (F) showed no relationship to
the cell surface densities of any coreceptors examined on CD4 lym-
phocytes or CD4 CD14 mononuclear phagocytes.

FIG. 4. Relationship between RT activity and HIV coreceptor ex-
pression relative to CD4 levels. (a) The RT activity produced by
PBMC from subjects 1 (■ ), 2 (Œ), 3 (), 4 (}), 5 ( ), and 6 (F)
represented in Table 1 was correlated with the HLE relative to CD4
(RFI) on CD4 CD14 mononuclear phagocytes but not with other
coreceptors. The computer-fit linear regression curve predicts y 
770  80x (r2  0.81, P  0.01), where y represents the RT activity
and x represents the HLE RFI. (b) Circulating 1PI, but not 2M, was
correlated with HLE RFI on CD4 CD14 mononuclear phagocytes
but not with other coreceptors on these cells. The computer-fit linear
regression curve predicts y  137  9x, where y represents the 1PI
and x represents the HLE RFI relative to CD4 (r2  0.88, P  0.006).
(c) The RT activity decreased as the circulating 1PI concentration
increased on day 8 as represented in Fig. 1. Computer-fit linear re-
gression of these data predict that log [y]  3.0  0.69 log [x], where
x represents the 1PI concentration in serum and y represents the in
vitro HIV RT activity (r2  0.95, P  0.001).

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These results suggest that circulating 1PI may modulate cell
surface HLE on peripheral blood mononuclear phagocytes,
thereby diminishing the number of HIV-responsive cells.
Although tropism was not addressed in the present study,
the relationship between RT activity and coreceptors on mono-
nuclear phagocytes suggests that the viral isolate used may
have been tropic for these cells. The dynamic relationship
between coreceptors on PBMC may not be consonant with
their relationship in lymph nodes or in tissue where differen-
tiation pathways are subject to the local environment; however,
these results suggest new targets for therapeutic intervention
which could potentially prolong or prevent the onset of the
symptomatic clinical status and AIDS.
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